ABSTRACf. High doses of intravenous immunoglobulin were given to seven pregnant women between the 27th and 36th wk of gestation who were at risk for preterm delivery. Determinations of IgG subclasses and of antibodies against group B streptococcal serotypes, pneumococcal polysaccharides, and tetanus toxoid were done in maternal serum before and after intravenous IgG infusion and after delivery in cord serum. Substantial transplacental passage of the infused material could be observed in five cases where delivery occurred at the 34th wk or later. After the 36th wk of gestation, IgG subclass and antibody concentrations in cord serum were increased up to the levels in the maternal serum. (Pediatr Res 20:933-936, 1986) Abbreviation IGIV, intravenous immunoglobulin Preterm neonates are known to be highly susceptible to systemic bacterial infections (1). This increased risk is due in part to the immaturity of the immune system and to an incomplete transplacental transfer of protective IgG antibodies from the mother (2-7). Sidiropoulos et al. (8) have shown that the administration of IGIV in combination with antibiotics was effective in the treatment of neonatal sepsis, particularly in premature babies. As a consequence of this previous work, the question was asked whether perinatal or prenatal infection could be prevented by giving IGIV to pregnant women who were at risk for preterm delivery. As a first step, we studied the possibility of a transplacental passage of IGIV administered in the last trimenon of pregnancy. This report provides evidence that all four IgG subclasses and various specific antibodies present in the IGIV preparation are transferred from the mothers to the babies.
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PATIENTS
The study included seven women between the 27th and the 36th wk of pregnancy who were at risk for preterm delivery with preterm labor, rupture of the membranes, or signs of chorioam-nionitis. The gestational age was assessed by serial ultrasonography and examination of the newborns. Informed consent was obtained from all women. Immunoglobulin applications consisted of intravenous infusions of 24 g IgG (Sandoglobulin) at each of5 consecutive days (6% solution in 0.9% saline, 10 drops/ min). In addition, the patients received the antibiotics amoxicillin (4 g/day) and clindamycin (1.8 g/day). Monitoring of pulse and blood pressure, cardiotocography, and clinical observation did not show any side effects attributable to IGIV in mothers and infants. Serum samples were obtained immediately before the first and after the last infusion. In three women in whom delivery was delayed for 8-25 days after the last infusion, additional samples were taken at the time of birth. Cord blood samples were collected at delivery. The serum was kept at -20 0 C until assayed.
METHODS
IgG subclasses. IgG subclass specific reagents were prepared by immunizing sheep with isolated myeloma proteins and quantitative determinations were done with a solid phase radioimmunoassay as described (9, 10) . Binding inhibition curves were established using the WHO reference plasma 67/69, the IgG subclass concentrations of which are known (9) .
Determination of antibodies. Determinations of antibodies to surface antigens of group B streptococci (types la, Ib, II, and III), to pneumococcal polysaccharides (types 6A, 19F, and 23F), and to tetanus toxoid were performed using radioimmunoassay and ELISA procedures are described in detail elsewhere (II, 12). Values were expressed in arbitrary units or in IU/m!. Table I summarizes the results of IgG subclass determinations in maternal and cord blood samples of six pregnancies. In the patients Ag and Th who were delivered after 28 wk of pregnancy, the IGIV infusions resulted in a pronounced increase of all fOUf IgG subclass serum concentrations. In Ag, cord blood subclass concentrations were lower than those observed in the maternal preinfusion sample and corresponded to values reported in the literature for that gestational age (2, 4, 5) . In Th, cord blood subclass levels were comparable to those observed in the maternal preinfusion sample and thus exceeded the expected values. In Ry and Le who were delivered at the 34th and 35th wk of gestation, the situation was complicated by long intervals between infusions and birth (11 and 25 days). Again, in the 934 MORELL ET AL. Maternal IgG is known to be transferred across the placenta, probably by an active transport mechanism involving Fc receptors for IgG molecules on the syncytiotrophoblast membrane (13, 14) . Fetal serum levels of the four IgG subclasses increase proportionally with the gestational age (2) (3) (4) (5) . At the normal term of delivery cord serum levels ofIgG and IgG subclasses are often found to be approximately 10% greater than the maternal levels (2-5, IS). A similar correlation to gestational age has been observed for levels of antibodies to group B streptococci (6, 7) . Their presence in cord serum was shown to reduce the susceptibility to neontal group B streptococcal infections (16) . To our knowledge, passage of other specific antibodies in relation to gestational age has not been reported. The pregnant women in the present study were at risk for preterm delivery and placental dysfunction could not be excluded. Nevertheless, the transport mechanism was still operative. Our results indicate that the placental Fc receptors and the subsequent steps involved in the transport across this biological barrier recognized and handled molecules of the infused immunoglobulin preparation such as endogenous IgG. This was demonstrated by the passage of all four IgG subclasses and of a number of antibodies specific for group B streptococcal and pneumococcal serotypes and for tetanus toxoid. As in physiological conditions, the extent of this transport depended on the gestational age. According to a limited passage at 28 wk, cord serum IgG subclass and antibody concentrations were lower than or similar to those in the maternal preinfusion samples. At 34 wk and particularly at 36 wk of gestation, the transport mechanism was working more effectively producing increments of IgG subclass and antibody concentrations in cord serum which were already visible 3 days after the start of the infusions. In view of the small number of patients studied, the data have to be interpreted with caution. However, there is evidence from this pilot study that high doses of IGIV given to mothers after approximately 34 wk of gestation could maternal sera a marked increase of all subclass levels was achieved by the infusions of IGIV. In cord serum of Ry, the IgG I level was higher than in the maternal preinfusion sample.
RESULTS
In addition IgG4 could be demonstrated in the cord serum, whereas in maternal preinfusion serum of Ry, this subclass was lacking. Similarly in samples from Le the IgG2 level was higher in cord than in preinfusion maternal serum. Patients Cr and Sc were delivered at the 36th and 37th wk of gestation. The IgG subclass concentrations in both cord sera were markedly higher than in the maternal preinfusion samples and approximated maternal values at the time of birth. Antibody levels determined in maternal and cord serum samples are shown in Table 2 . Immunoglobulin infusions were followed by an increase of all antibody concentrations in the maternal sera. In cord blood of the babies born after 28 wk of pregnancy, antibody concentrations were lower than or similar to those in the maternal preinfusion samples. A different situation was noticed at the 34th and 35th wk of gestation, where cord serum antibody levels were generally higher than in corresponding maternal preinfusion samples but still below maternal values at the time of delivery. These data were corroborated by the findings in another pregnancy (Fig. I) : patient Sb had received three infusions of 24 g IGIV each at 3 consecutive days when spontaneous delivery took place in the 35th wk of pregnancy. Even at this short interval between infusions and birth, cord serum levels ofantibodies to group B streptococcal antigens exceeded preinfusion levels and approached values of the maternal sample at delivery. Finally, Table 2 shows the antibody concentrations observed in serum samples from Cr and Sc who were delivered after 36 and 37 wk of gestation. In both cord sera, antibody levels were close or identical to those in maternal serum at the time of birth and thus markedly higher than in the preinfusion maternal sera. Thus, the IgG subclass concentrations and the data from antibody determinations in maternal and cord sera are in agreement. Taken all together, the results provide evidence for significant transplacental passage ofIGIV. (17) . One types of antibodies to GBS Fig. I . Concentrations of antibodies to group B streptococci of types la, Ib, II, and III (arbitrary units in cpm) in serum samples from patient Sb. Delivery was in the 35th wk of gestation after three infusions of a total of 72 g Sandoglobulin. The infusions resulted in an increase of all four antibody levels in maternal serum. Note that anti-la, anti-H, and anti-III concentrations in cord serum were markedly higher than in the maternal preinfusion sample taken 3 days before delivery. would assume that these procedures had an influence on transplacental passage. Recently, a modified IgG preparation used for replacement therapy in two-antibody-deficient mothers was shown to cross the placental barrier (I8). Apparently, treatment ofIgG molecules ofthis preparation with reducing and alkylating agents did not abolish this biological property. The existence of quantitative differences between IGIV preparations in this respect will have to be demonstrated in future studies.
